Yubo International Biotech Ltd financial data

Symbol
YBGJ on OTC
Industry
Electromedical & Electrotherapeutic Apparatus
Location
Room 105, Building 5, 31 Xishiku Avenue, Beijing, China
State of incorporation
NY
Fiscal year end
December 31
Former names
MAGNA LAB INC (to 12/4/2020)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 17.4 % -25.9%
Quick Ratio 2.05 % -71.7%
Debt-to-equity -155 % +39.2%
Return On Equity 73.3 % -24.4%
Return On Assets -123 % -96.1%
Operating Margin -51K % -25716%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares 0%
Entity Public Float 43.4K USD
Weighted Average Number of Shares Outstanding, Diluted 120M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.47K USD -99.4%
Operating Income (Loss) -1.77M USD -48.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.98M USD -65.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.98M USD -65.8%
Earnings Per Share, Diluted -0.01 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.02K USD +10.3%
Inventory, Net 37K USD -82.8%
Assets, Current 683K USD -5.86%
Property, Plant and Equipment, Net 206K USD -45.1%
Operating Lease, Right-of-Use Asset 479K USD +22.2%
Intangible Assets, Net (Excluding Goodwill) 50.5K USD -7.14%
Assets 1.53M USD -7.94%
Liabilities, Current 4.72M USD +39.1%
Operating Lease, Liability, Noncurrent 111K USD -4.12%
Liabilities 4.83M USD +37.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 127K USD
Retained Earnings (Accumulated Deficit) -6.66M USD -36.3%
Stockholders' Equity Attributable to Parent -3.42M USD -85.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -3.3M USD -78.9%
Liabilities and Equity 1.53M USD -7.94%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120K USD -269%
Net Cash Provided by (Used in) Financing Activities 98K USD
Net Cash Provided by (Used in) Investing Activities -30K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.7K USD +322%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.02K USD +10.3%
Deferred Tax Assets, Valuation Allowance 1.54M USD +46.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.17 pure 0%
Operating Lease, Liability 579K USD
Payments to Acquire Property, Plant, and Equipment 18.9K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -1.84M USD -43.9%
Lessee, Operating Lease, Liability, to be Paid 495K USD +23.6%
Property, Plant and Equipment, Gross 228K USD -59.5%
Operating Lease, Liability, Current 368K USD +33.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 383K USD +275%
Lessee, Operating Lease, Liability, to be Paid, Year One 390K USD +283%
Lessee, Operating Lease, Liability, to be Paid, Year Three 112K USD +559%
Deferred Tax Assets, Operating Loss Carryforwards 1.45M USD
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -102K USD -29.3%
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 17K USD
Additional Paid in Capital 2.99M USD +1.85%
Amortization of Intangible Assets 13.4K USD +14.7%
Depreciation, Depletion and Amortization 170K USD -4.73%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 49 USD -62.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%